Related Experiment Videos
[Long-term therapy of hypercholesteremia in diabetics with colestipol]
Insights
Colestipol effectively lowered cholesterol in hypercholesterolemic diabetics over three years. While some experienced increased triglycerides and initial gastrointestinal issues, side effects resolved with continued treatment.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Context:
- Hypercholesterolemia is a significant risk factor for cardiovascular disease, particularly in diabetic patients.
- Diabetic dyslipidemia often requires therapeutic intervention to mitigate associated health risks.
Purpose:
- To evaluate the long-term efficacy and safety of Colestipol in managing hypercholesterolemia in diabetic individuals.
- To assess the impact of Colestipol on serum cholesterol and triglyceride levels over a 3-year treatment period.
Summary:
- A 3-year study involving 64 hypercholesterolemic diabetics demonstrated an average 29% reduction in serum cholesterol levels with Colestipol treatment.
- While Colestipol was generally well-tolerated, some patients experienced transient increases in triglyceride levels and initial gastrointestinal complaints, which resolved with continued therapy.
- Routine laboratory tests remained within normal ranges, indicating no significant systemic adverse effects.
Impact:
- Colestipol offers a viable long-term therapeutic option for reducing cholesterol in diabetic patients with hypercholesterolemia.
- Understanding the side effect profile, including transient triglyceride changes and gastrointestinal issues, is crucial for patient management and adherence.
- This study contributes to the evidence base for managing dyslipidemia in complex patient populations, such as those with diabetes.
Abstract:
64 hypercholesterolemic diabetics (17 males and 47 females) were treated with Colestipol for 3 years. An average reduction of 29% in serum cholesterol levels was observed after 3 years. An increase in triglyceride levels was observed in several instances. Other laboratory data failed to reveal any deviation from normal ranges. Gastrointestinal complaints and constipation were initially noted with onset of therapy. These side effects resolved with continuation of treatment.